๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shantou
Clinical trial register · China

Clinical Trials in Shantou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University13 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University7 Novartis Pharmaceuticals6 Merck Sharp & Dohme LLC5 BeiGene3
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Shantou

97 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration
NCT07776522Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
West China Hospital
Phase 2
50
Beijing, Jilin City, Chongqing, Shantou, Zhejiang, Harbin, Zhengzhou, Wuhan
2026-08-31
Not yet open
Phase III Study of OT202 in Treating Moderate to Severe Dry Eye
NCT07740564Dry Eye
Ocumension Therapeutics (Suzhou) Co., Ltd
Phase 3
842
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou
2026-08
Recruiting
Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma
NCT07586124Head and Neck Squamous Cell Carcinoma
Lepu Biopharma Co., Ltd.
Phase 2
80
Beijing, Fuzhou, Guangzhou, Shantou, Nanning, Shijiazhuang, Wuhan, Changsha
2026-07-06
Recruiting
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
NCT07492641HR+/HER2- Breast Cancer
BeOne Medicines
Phase 3
1,056
Bengbu, Beijing, Chongqing, Fuzhou, Guangzhou, Shantou, Nanning, Haikou
2026-05-22
Not yet open
Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II Study
NCT07589049Head and Neck Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2
42
Foshan, Guangzhou, Qingyuan, Shantou, Shenzhen, Zhanjiang, Ganzhou
2026-05
By invitation
BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression
NCT07618624Recurrent Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Sun Yat-sen University
Phase 2
42
Foshan, Guangzhou, Shantou, Shenzhen, Zhanjiang
2026-04-20
Recruiting
A Study of E6742 in Participants With Systemic Lupus Erythematosus
NCT07515014Systemic Lupus Erythematosus
Eisai Co., Ltd.
Phase 2
256
Bengbu, Beijing, Chongqing, Guangzhou, Shantou, Nanning, Guiyang, Luoyang
2026-03-31
Recruiting
A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy
NCT07777861Primary Open-Angle Glaucoma, Optic Nerve Injury
Qingdao WanMing BioCell Pharmaceutics Co.,Ltd.
Phase 2
90
Beijing, Guangzhou, Shantou, Changsha, Tianjin, Hangzhou, Wenzhou
2026-03-18
Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
Phase 3
850
Beijing, Chongqing, Fuzhou, Shantou, Shenzhen, Zhengzhou, Jingzhou, Wuhan
2026-03-16
Recruiting
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 โ‰ฅ 50%. (ROSETTA Lung-202)
NCT07361510Non-Small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
Phase 3
750
Beijing, Fuzhou, Xiamen, Zhangzhou, Guangzhou, Shantou, Nanning, Harbin
2026-03-12
Recruiting
Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer
NCT07367516Esophageal Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
105
Hefei, Beijing, Fuzhou, Lanzhou, Shantou, Nanning, Guangxi, Zunyi
2026-02-12
Recruiting
Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy
NCT07400523Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
446
Zhanjiang, Guangzhou, Shantou
2026-02-10
Recruiting
Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)
NCT07317934Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Innostellar Biotherapeutics Co.,Ltd
Phase 3
388
Hefei, Beijing, Chongqing, Guangzhou, Shantou, Zhongshan, Xingtai, Harbin
2026-01-14
Active, closed
DIEP-MDS for Risk Stratification of Flap Vascular Compromise and Failure in Breast Reconstruction
NCT07761390Breast Neoplasms, Breast Reconstruction, Postoperative Complications
Zhuliling
Observational
1,500
Xiamen, Dongguan, Guangzhou, Huizhou, Meizhou, Shantou, Shanwei, Shaoguan
2026-01-01
Recruiting
JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.
NCT07284134Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
560
Hefei, Beijing, Fuzhou, Lanzhou, Wuwei, Guangzhou, Meizhou, Shantou
2025-12-24
Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing
ArriVent BioPharma, Inc.
Phase 3
480
Beijing, Xiamen, Foshan, Shantou, Shijiazhuang, Harbin, Luoyang, Xinxiang
2025-12-17
Recruiting
Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
NCT07311772Nasopharyngeal Cancinoma (NPC), Radiation-induced Oral Mucositis
Sun Yat-sen University
Phase 3
386
Beijing, Fuzhou, Guangzhou, Shantou, Zhuhai, Nanning, Wuzhou, Changsha
2025-12-16
Recruiting
A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy
NCT07375316Non Small Cell Lung Cancer
Guangdong Association of Clinical Trials
Phase 2
120
Guangzhou, Meizhou, Shantou, Shenzhen
2025-12-15
Recruiting
Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
NCT07339488Borderline Resectable Carcinoma, Unresectable Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Immune Checkpoint Inhibitor
Chuangzhen Chen
Phase 2
43
Shantou
2025-12-05
Recruiting
40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
NCT07328854Nasopharyngeal Carcinoma
Ming-Yuan Chen
Phase 3
346
Hefei, Fuzhou, Guangzhou, Shantou, Zhongshan, Zhuhai, Nanning, Wuzhou
2025-11-20
Recruiting
Neuroendoscopy-assisted Drainage Versus Burr Hole Drainage for Chronic Subdural Hematoma
NCT07144423Chronic Subdural Hematoma
Beijing Tiantan Hospital
Not applicable
770
Beijing, Xiamen, Jiangmen, Shantou, Shenzhen, Liuzhou, Nanning, Wuzhou
2025-11-19
Recruiting
Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
NCT07328841Nasopharyngeal Carcinoma (NPC)
Ming-Yuan Chen
Phase 3
456
Guangzhou, Shantou, Zhongshan, Nanning, Wuzhou, Wuhan, Changsha, Guangdong
2025-11-18
Active, closed
Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.
NCT07201337Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 3
700
Dongguan, Guangzhou, Shantou, Shenzhen, Zhanjiang
2025-11-17
Recruiting
Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
NCT07110415Coronary Heart Disease, Cardiac Dysfunction
SPH Qingdao Growful Pharmacetical Co.,Ltd
Phase 4
2,708
Haozhou, Beijing, Chongqing, Lanzhou, Guangzhou, Shantou, Zhuhai, Guilin
2025-11-06
Recruiting
A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
NCT07187440Fabry Disease
Takeda
Observational
200
Hefei, Beijing, Fuzhou, Hangzhou, Shantou, Shenzhen, Shijiazhuang, Harbin
2025-11-01
Recruiting
Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement
NCT07104604Rectal Cancer
Affiliated Cancer Hospital of Shantou University Medical College
Phase 2
51
Shantou
2025-10-20
Recruiting
Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors
NCT07071103Radiotherapy, Metastatic Solid Cancers, Immune Checkpoint Blockade, Esophageal Neoplasms Malignant
Chuangzhen Chen
Phase 2
48
Shantou
2025-09-26
Recruiting
A Study of Pegmolesatide of in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI)
NCT07136792Renal Anemia of Chronic Kidney Disease
Guangdong Provincial People's Hospital
Not applicable
96
Beijing, Longyan, Zhangzhou, Guangzhou, Meizhou, Shantou, Shaoguan, Zhongshan
2025-09-08
Recruiting
Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer
NCT07095023Breast Cancers
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
112
Beijing, Guangzhou, Shantou, Nanning, Guiyang, Haikou, Wenzhou, Shenzhen
2025-08-15
Recruiting
To Investigate REKOVELLE in Chinese Women Undergoing Assisted Reproductive Technologies: Effectiveness, Safety, and Patterns of Use in Real-world Practice
NCT07029451Infertility
Ferring Pharmaceuticals
Observational
2,500
Hefei, Maโ€™anshan, Beijing, Chaoyang, Xicheng, Guangzhou, Shantou, Nanning
2025-08-05
Not yet open
A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia
NCT07146386Benign Prostatic Hyperplasia, Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms
Shanghai Huilun Pharmaceutical Co., Ltd.
Phase 3
728
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Zhangzhou, Dongguan, Shantou
2025-08
Recruiting
A Registry๏ผš Siltartoxatug Injection for Tetanus Prophylaxis Following Injury
NCT07107932Tetanus
Zhuhai Trinomab Pharmaceutical Co., Ltd.
Observational
10,000
Shantou, Xiangyun, Shaoxing, Zhoushan
2025-07-31
Recruiting
TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer
NCT07044908RAS/BRAF Wild Type Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
72
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Meizhou, Shantou, Nanning
2025-07-30
Recruiting
A Multi-center Study on Artificial Intelligence-Based Quantitative Evaluation of Echocardiography
NCT07133516Artificial Intelligence (AI), Artificial Intelligence (AI) in Diagnosis, Cardiovascular Diseases (CVD), Echocardiography
First Hospital of China Medical University
Observational
1,600
Huainan, Fuzhou, Meizhou, Shantou, Shenzhen, Baise City, Guilin, Liuzhou
2025-07-22
Recruiting
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
NCT07003074Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
642
Hefei, Beijing, Lanzhou, Shantou, Harbin, Kaifeng, Puyang, Zhengzhou
2025-06-23
Recruiting
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
NCT06340568Endometrial Cancer
BioNTech SE
Phase 3
480
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shantou
2025-06-10
Recruiting
Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Esophageal Carcinoma
NCT06979869Esophageal Cancer
Xijing Hospital
Observational
300
Wuwei, Shantou, Zhaoqing, Zhengzhou, Xi'an, Yanโ€™an, Taiyuan, Chengdu
2025-05-26
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504Endometrial Cancer
Merck Sharp & Dohme LLC
Phase 3
1,123
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang
2025-05-22
Recruiting
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
NCT06711887Lupus Nephritis
Novartis Pharmaceuticals
Phase 3
348
Guangzhou, Shantou, Shenzhen, Liuzhou, Wuhan, Changchun, Shenyang, Binzhou
2025-05-19
Recruiting
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
NCT06947993Atopic Dermatitis
Novartis Pharmaceuticals
Phase 2
224
Guangzhou, Shantou, Changsha, Changchun, Hangzhou, Beijing, Shanghai
2025-05-16
Active, closed
Neoadjuvant Therapy ๏ผˆNALIRIFOX๏ผ‰ for Locally Advanced Colon and Upper Rectal Cancer
NCT07020468Colorectal Cancer (CRC)
Affiliated Cancer Hospital of Shantou University Medical College
Phase 4
57
Shantou
2025-05-15
Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310Carcinoma, Non-Small-Cell Lung
Mirati Therapeutics Inc.
Phase 3
630
Bengbu, Hefei, Beijing, Chongqing, Fuzhou Fujian, Xiamen, Guangzhou, Shantou
2025-04-24
Recruiting
Development of an AI-Agent for Urological Disease Diagnosis and Treatment
NCT07721935Urinary Stones, Prostate Cancer, Bladder Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
2,000
Guangzhou, Shantou, Ganzhou
2025-04-01
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
NCT06646276Extensive-Stage Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 3
530
Beijing, Chongqing, Fuzhou, Xiamen, Shantou, Harbin, Wuhan, Changsha
2025-02-25
Recruiting
A Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Breast Cancer Patients
NCT06811870Breast Cancers
Guangdong Provincial People's Hospital
Phase 1/2
161
Guangzhou, Shantou
2025-02-01
By invitation
Catheter Ablation for Functional Mitral Regurgitation in Persistent Atrial Fibrillation: Development and Validation of a Predictive Model-A Multicenter Prospective Cohort Study
NCT07096219AF Ablation Patients With Moderate+ FMR and Persistent AF
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
556
Guangzhou, Shantou
2024-12-31
Not yet open
Chidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast Cancer
NCT06750848Advanced Breast Cancer
Jundong Wu
Phase 2
48
Shantou
2024-12-20
Recruiting
Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients๏ผˆRocket Trial๏ผ‰
NCT06647940Diffuse Large B Cell Lymphoma (DLBCL)
Sun Yat-sen University
Phase 2
39
Guangzhou, Lanzhou, Dongguan, Shantou, Shenzhen, Zhaoqing, Zhuhai
2024-11-01
Recruiting
Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
NCT06637163Esophageal Squamous Cell Carcinoma
Shanghai Zhongshan Hospital
Phase 2
100
Shantou, Shenyang, Shanghai, Tianjin, Hangzhou
2024-10-24
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors
NCT06656390Advanced Cancer, Advanced Solid Tumors
Shanghai Allink Biotherapeutics Co., Ltd.
Phase 1/2
202
Hefei, Fuzhou, Xiamen, Guangzhou, Shantou, Nanning, Chengde, Harbin
2024-10-24
Recruiting
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
NCT06629779Metastatic Castration-Resistant Prostate Cancer
Pfizer
Phase 3
900
Wuhu, Beijing, Fuzhou, Guangzhou, Shantou, Guilin, Xinxiang, Zhengzhou
2024-10-22
Recruiting
A Study in Chinese Patients With Acquired Blepharoptosis
NCT06683651Blepharoptosis
Santen Pharmaceutical Co., Ltd.
Phase 3
180
Hefei, Beijing, Shantou, Guiyang, Zhengzhou, Haโ€™erbin, Wuhan, Xiangyang
2024-10-22
Recruiting
Efficacy Evaluation Study of BAT5906 and Lucentisยฎ in Patients With Diabetic Macular Edema
NCT07515079Diabetic Macular Edema (DME)
Bio-Thera Solutions
Phase 3
406
Beijing, Chongqing, Lanzhou, Guangzhou, Shantou, Shenzhen, Nanning, Zunyi
2024-10-09
Recruiting
Efficacy and Safety of SR1375 in Adult Patients With CAP
NCT06577558Community-acquired Pneumonia
Shanghai SIMR Biotechnology Co., Ltd.
Phase 2
240
Fuyang, Beijing, Zhangzhou, Gaozhou, Guangzhou, Shantou, Yulin, Shijiazhuang
2024-09-10
Recruiting
Methotrexate Combined With Tofacitinib in Rheumatoid Arthritis
NCT06301373Rheumatoid Arthritis
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
130
Foshan, Guangzhou, Jieyang, Shantou
2024-09-01
Recruiting
Long-Term Outcomes of Endoscopic-assisted vs Conventional Breast-conserving Surgery in Breast Cancer Patients After Neoadjuvant Therapy: a Randomized, Multicenter, Open Label, Non-inferiority Trial
NCT06716073Breast Cancer Invasive
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
1,380
Guangzhou, Shantou
2024-08-01
Recruiting
Accuracy of LAA Occluder Size Selection: CT vs. DSA During Combined AF Ablation and LAA Occlusion
NCT06455644Atrial Fibrillation, Arrhythmias, Cardiac, Heart Diseases, Cardiovascular Diseases
First Affiliated Hospital of Shantou University Medical College
Not applicable
238
Foshan, Meizhou, Shantou, Zhongshan
2024-07
Recruiting
GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
NCT06455410Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
216
Foshan, Guangzhou, Liuzhou, Nanning, Shantou, Shenzhen, Zhangjiang
2024-06-18
Recruiting
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
NCT06133972Systemic Lupus Erythematosus
Novartis Pharmaceuticals
Phase 3
550
Guangzhou, Shantou, Nanjing, Suzhou, Nanchang, Pingxiang, Changchun, Linyi
2024-05-21
Recruiting
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
NCT06307665Asthma
AstraZeneca
Phase 3
440
Beijing, Bengbu, Chengdu, Chongqing, Hohhot, Mianyang, Shanghai, Shantou
2024-05-20
Active, closed
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
NCT06439576Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion
Hoffmann-La Roche
Observational
1,000
Shantou, Luoyang, Shiyan, Xuzhou, Fushun, Panjin, Shenyang, Weifang
2024-05-09
Active, closed
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
NCT06356311Gastroesophageal Cancer
Merck Sharp & Dohme LLC
Phase 3
450
Hefei, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Nanning, Shijiazhuang
2024-05-03
Not yet open
Enhanced External Counter Pulsation on Afterload Mismatch Rate in Post-TEER (PAMPER)
NCT06227286Mitral Regurgitation
Sun Yat-sen University
Not applicable
176
Guangzhou, Jieyang, Shantou, Zhongshan
2024-03-01
Recruiting
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
NCT06239727Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
593
Fuzhou, Xiamen, Dongguan, Foshan, Guangzhou, Shantou, Zhanjiang, Nanning
2024-03-01
Recruiting
A Study of YL202 in Selected Patients With Advanced Solid Tumors
NCT06107686NSCLC, Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2
200
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Shantou, Guilin
2023-12-15
Active, closed
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958Endometrial Cancer
Merck Sharp & Dohme LLC
Phase 3
710
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang, Nanning
2023-12-06
Recruiting
Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma
NCT05984342Esophageal Squamous Cell Carcinoma
Affiliated Cancer Hospital of Shantou University Medical College
Phase 1
50
Shantou
2023-08-02
Active, closed
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT05843643Systemic Lupus Erythematosus
AbbVie
Phase 3
1,014
Bengbu, Beijing, Xiamen, Guangzhou, Shantou, Nanning, Luoyang, Wuhan
2023-07-25
Recruiting
Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)
NCT05904964HR Positive/HER2 Low Expression Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
288
Guangzhou, Shantou, Qionghai
2023-07-01
Active, closed
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma
NCT05126719Recurrent or Metastatic Nasopharyngeal Carcinoma
Lepu Biopharma Co., Ltd.
Phase 2
238
Beijing, Chongqing, Fuzhou, Guangzhou, Maoming, Shantou, Shaoguan, Zhongshan
2023-04-06
Active, closed
Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC
NCT05765825Extensive-stage Small-cell Lung Cancer
Sichuan University
Phase 2
61
Chongqing, Shantou, Wuhan, Shenyang, Jinan, Shanghai, Chengdu, Guiyang
2023-03-07
Active, closed
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
NCT05639114Systemic Lupus Erythematosus
Novartis Pharmaceuticals
Phase 3
436
Guangzhou, Shantou, Haikou, Zhuzhou, Nanjing, Suzhou, Nanchang, Pingxiang
2023-03-02
Active, closed
A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
NCT05609370Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
BeiGene
Phase 1/2
113
Hefei, Beijing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Shantou, Zhengzhou
2023-01-29
Recruiting
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
NCT05712200Atrial Fibrillation (AF)
Anthos Therapeutics, Inc.
Phase 3
2,500
Beijing, Lanzhou, Guangzhou, Shantou, Nanning, Shijiazhuang, Wuhan, Changchun
2022-12-27
Recruiting
Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
NCT06551220Metastatic Breast Cancer
Sun Yat-sen University
Observational
800
Fuzhou, Dongguan, Foshan, Guangzhou, Shantou, Shaoguan, Shenzhen, Zhongshan
2022-10-10
Recruiting
OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method
NCT05450835Gastric Cancer
Nanfang Hospital, Southern Medical University
Not applicable
344
Quanzhou, Guangzhou, Shantou, Ganzhou, Changsha, Hengyang, Changchun, Shenyang
2022-09-01
Recruiting
Adjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD
NCT05457049Non Small Cell Lung Cancer
Guangdong Association of Clinical Trials
Observational
180
Foshan, Guangzhou, Shantou, Zhongshan
2022-08-01
Active, closed
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
NCT05126277Lupus Nephritis
Novartis Pharmaceuticals
Phase 3
452
Guangzhou, Shantou, Shenzhen, Liuzhou, Haikou, Wuhan, Changsha, Nanjing
2022-07-14
Active, closed
TAB014 Compared to Lucentisยฎ in Patients with Neovascular Age-related Macular Degeneration
NCT05461339Neovascular Age-related Macular Degeneration
BioDlink Biopharm Co., Ltd.
Phase 3
488
Hefei, Beijing, Jilin City, Chongqing, Fuzhou, Guangzhou, Shantou, Shenzhen
2022-06-28
Active, closed
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
NCT05239741Colorectal Neoplasms
Merck Sharp & Dohme LLC
Phase 3
100
Beijing, Tianjin, Chongqing, Fuzhou, Guangzhou, Shantou, Nanning, Harbin
2022-04-02
Recruiting
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT04928846Non Small Cell Lung Cancer
AbbVie
Phase 3
768
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang
2022-03-25
Active, closed
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
NCT05173987Endometrial Neoplasms
Merck Sharp & Dohme LLC
Phase 3
280
Hefei, Beijing, Chongqing, Fulingqu, Fuzhou, Guangzhou, Shantou, Zhanjiang
2022-02-03
Recruiting
A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.
NCT07392736Solid Tumor
Advenchen Laboratories, LLC
Phase 1/2
228
Beijing, Hunan, Fuzhou, Shantou, Shaoguan, Guilin, Liuzhou, Nanning
2021-10-26
Active, closed
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT04974398Nasopharyngeal Carcinoma
Akeso
Phase 3
296
Hefei, Fuzhou, Xiamen, Dongguan, Guangzhou, Jiangmen, Shantou, Shenzhen
2021-08-16
Recruiting
Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index
NCT05728268Breast Cancer
Shantou Central Hospital
Phase 2
64
Shantou
2021-08-01
Recruiting
Aortic Valve Diseases RISk facTOr assessmenT and Prognosis modeL Construction
NCT06069232Aortic Valve Disease
Sun Yat-sen University
Observational
2,000
Guangzhou, Jieyang, Shantou, Shenzhen, Zhanjiang, Zhongshan
2021-03-01
Recruiting
Postoperative Hypoxemia Increases the Risk of Anastomotic Leak After Radical Esophagectomy
NCT07309991Esophageal Carcinoma, Esophageal Adenocarcinoma, Esophagectomy, PaO2
Sun Yat-sen University
Observational
2,500
Guangzhou, Shantou, Shijiazhuang, Shanghai, Chengdu, Nanchong
2021-01-01
Recruiting
Secukinumab Open Label Roll-over Extension Protocol
NCT04638647Autoimmunity, Inflammation
Novartis Pharmaceuticals
Phase 4
1,000
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Shantou, Shenzhen, Wuhan
2020-12-22
Active, closed
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
NCT04464226Cancer
Bayer
Phase 3
402
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Shenzhen
2020-10-20
Recruiting
Thrombus Aspiration in STEMI Patients With High Thrombus Burden
NCT04212494ST-segment Elevation Myocardial Infarction (STEMI)
Guangdong Provincial People's Hospital
Not applicable
3,838
Fuzhou, Foshan, Guangzhou, Huizhou, Jiangmen, Kaiping, Maoming, Shantou
2020-08-30
Active, closed
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
NCT04379635Non Small Cell Lung Cancer
BeiGene
Phase 3
453
Hefei, Beijing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Jiangmen, Shantou
2020-05-29
Active, closed
Study of Porcine Fibrin Sealant in Preventing Cervical Anastomotic Leakage (PLACE030)
NCT03847857Esophageal Anastomotic Leak
Sun Yat-sen University
Phase 3
360
Guangzhou, Jieyang, Shantou, Zhongshan, Chengdu, Shanghai
2019-02-21
Recruiting
Longitudinal Cohort Study of Immune-Related Adverse Events in Solid Tumor Patients Treated With Immune Checkpoint Inhibitors
NCT07357636Solid Tumor, Immune-Related Adverse Events, Immunotherapy Toxicity
Shantou University Medical College
Observational
940
Fuzhou, Guangzhou, Sanya, Shantou, Zhengzhou
2019-01-10
Recruiting
Biomarkers for Prediction of Tumor Response to Radiotherapy
NCT03744819Solid Tumors
Chuangzhen Chen
Observational
100
Shantou
2018-10-29
Active, closed
Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer
NCT03519230Ovarian Cancer
BeiGene
Phase 3
224
Hefei, Beijing, Chongqing, Guangzhou, Shantou, Nanning, Harbin, Zhengzhou
2018-05-14
Recruiting
Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer
NCT04263298Metastatic Breast Cancer
Herui Yao
Phase 3
210
Guangzhou, Shantou, Shenzhen, Zhangjiang, Zhuhai, Nanning, Changsha
2018-05-01
Recruiting
Tricuspid RegurgitAtion rIsk modeL Study (TRAIL Study)
NCT06926959Tricuspid Regurgitation
Sun Yat-sen University
Observational
3,000
Guangzhou, Jieyang, Shantou, Shenzhen, Zhanjiang, Zhongshan
2016-06-15
Rows per page Showing 1–97 of 97
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/shantou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 97 of those studies with a site in Shantou.

How many clinical trials are recruiting in Shantou?

70 of the 97 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 5 have not yet opened recruitment, 20 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shantou), 97 studies
PhaseStudiesRecruitingShare
Phase 3422643.3%
Phase 2201520.6%
Observational161316.5%
Not applicable989.3%
Phase 1/2656.2%
Phase 4323.1%
Phase 1111%

Most active sponsors

Lead sponsors with the most studies (Shantou)
Lead sponsorStudiesRecruiting
Sun Yat-sen University138
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University76
Novartis Pharmaceuticals64
Merck Sharp & Dohme LLC51
Affiliated Cancer Hospital of Shantou University Medical College32
BeiGene30
Bristol-Myers Squibb33
Chuangzhen Chen33
Guangdong Provincial People's Hospital33
AbbVie21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.